Chronic hepatitis C affects approximately 71 million people globally, with Egypt suffering from one of the highest burdens. Ravidasvir
, in combination with other hepatitis C treatments, could support new national as well as global goals to eliminate the virus.
Dr. Sherine Helmy, CEO, Pharco Pharmaceuticals 21 April 2017
We are happy to work together with the MPP and Bristol-Myers Squibb (BMS) to improve health outcomes by providing access to new and affordable therapies to developing countries.
Pankaj R. Patel, Zydus Chairman and Managing Director 01 July 2016